A shortage of mental health-care providers, coupled with pharmacists’ unique skills and access to patients, has led to a significant opportunity for community and health-system pharmacists to aid in detection of depression and in medication selection and counseling for patients with depression.
Mylan received approval from FDA to market its desvenlafaxine extended-release tablets, the generic version of Pristiq (Pfizer), for major depressive disorder. Plus, 2 other manufacturers recently received approval for their generic versions of Pristiq.
As fee-for-service rapidly transforms into value-based care, the industry must improve member engagement and outcomes by using targeted care management interventions that help deliver bottom-line results across a broader spectrum of the population.
A recent study provides more evidence that patients with psoriasis–even mild cases–face a higher risk of major depression, a finding that could lead dermatologists to alert patients with the condition and even screen them for mental health issues.
For Contemporary Pediatrics, Dr Bobby Lazzara discusses a recent study published in Pediatrics that examined why kids and teens are committing suicide; how they are doing it; and what groups were most likely to do it.